Trial Profile
Phase I trial evaluating the tolerability of low-dose vs high-dose sufentanil/triazolam vs sufentanil alone in patients undergoing office-based procedures
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Sufentanil/triazolam (Primary) ; Sufentanil
- Indications Anxiety disorders; Procedural pain
- Focus Adverse reactions
- 09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc
- 22 Jan 2009 New trial record.
- 12 Jan 2009 Results reported by AcelRx in a media release.